Manipulating mast cell microlocalisation and functional responses in NSCLC, for example through the inhibition of PGE2 production using cyclooxygenase-2 inhibitors, may offer a novel approach to the treatment of this disease. Here, PTGS2 is linked to non-small cell lung carcinoma.